Evidence map›Paper›PMID 30265691›Full record

ArticlePloS one2018

Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection.

T J De Wolfe, S Eggers, A K Barker, A E Kates, K A Dill-McFarland, G Suen, N Safdar

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04171466 (A Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy of a Multi-strain Synbiotic), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04171466 nacompletednot on this mapstarted 2020, after this paper: background citation

A Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy of a Multi-strain Synbiotic (SH-DS01) to Restore Gut Barrier Integrity and Gut Microbiota Composition After Antibiotic Administration.

TypeinterventionalSponsorSeed HealthRan2020 to 2022Enrolled46ConditionsAntibiotic Side Effect, Antibiotic-associated Diarrhea, Antibiotic-induced Dysbiosis, Antibiotic-induced Epithelial Barrier DisintegrityArmsCiprofloxacin + Metronidazole, SH-DS01, Placebo
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Antibiotic-perturbed microbiota and the role of probiotics.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  8. Review
  9. The host genes influencingFrontiers in cellular and infection microbiology · 2025
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Pathogens (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

T J De WolfeDepartment of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.ORCID 0000-0001-6261-1235
S EggersDepartment of Population Health Sciences, University of Wisconsin - Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.
A K BarkerDepartment of Population Health Sciences, University of Wisconsin - Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.
A E KatesDepartment of Medicine, Division of Infectious Disease, University of Wisconsin - Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.
K A Dill-McFarlandDepartment of Bacteriology, University of Wisconsin - Madison, Madison, Wisconsin, United States of America.
G SuenDepartment of Bacteriology, University of Wisconsin - Madison, Madison, Wisconsin, United States of America.
N SafdarDepartment of Medicine, Division of Infectious Disease, University of Wisconsin - Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.
University of Wisconsin–Madison · US

Funding

INTEGRATED TRAINING FOR PHYSICIAN-SCIENTISTST32GM008692 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BURKARD, MARK E · 1998 to 2020
$10.3M
Probiotics to Improve Outcomes of Clostridium difficileR03AG040669 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI SAFDAR, NASIA · 2012 to 2013
$146k
NIA NIH HHS R03 AG040669NIGMS NIH HHS T32 GM008692
6 · The paper itself

Abstract

Perturbations in the gastrointestinal microbiome caused by antibiotics are a major risk factor for Clostridium difficile infection (CDI). Probiotics are often recommended to mitigate CDI symptoms; however, there exists only limited evidence showing probiotic efficacy for CDI. Here, we examined changes to the GI microbiota in a study population where probiotic treatment was associated with significantly reduced duration of CDI diarrhea. Subjects being treated with standard of care antibiotics for a primary episode of CDI were randomized to probiotic treatment or placebo for 4 weeks. Probiotic treatment consisted of a daily multi-strain capsule (Lactobacillus acidophilus NCFM, ATCC 700396; Lactobacillus paracasei Lpc-37, ATCC SD5275; Bifidobacterium lactis Bi-07, ATCC SC5220; Bifidobacterium lactis B1-04, ATCC SD5219) containing 1.7 x 1010 CFUs. Stool was collected and analyzed using 16S rRNA sequencing. Microbiome analysis revealed apparent taxonomic differences between treatments and timepoints. Subjects administered probiotics had reduced Verrucomicrobiaceae at week 8 compared to controls. Bacteroides were significantly reduced between weeks 0 to 4 in probiotic treated subjects. Ruminococcus (family Lachnospiraceae), tended to be more abundant at week 8 than week 4 within the placebo group and at week 8 than week 0 within the probiotic group. Similar to these results, previous studies have associated these taxa with probiotic use and with mitigation of CDI symptoms. Compositional prediction of microbial community function revealed that subjects in the placebo group had microbiomes enriched with the iron complex transport system, while probiotic treated subjects had microbiomes enriched with the antibiotic transport system. Results indicate that probiotic use may impact the microbiome function in the face of a CDI; yet, more sensitive methods with higher resolution are warranted to better elucidate the roles associated with these changes. Continuing studies are needed to better understand probiotic effects on microbiome structure and function and the resulting impacts on CDI.

Indexed as

Administration, OralAnti-Bacterial AgentsBifidobacteriumClostridium InfectionsGastrointestinal MicrobiomeHumansLactobacillusProbioticsAnti-Bacterial Agents

Identifiers

PMID30265691
PMCPMC6161886
OpenAlexW2894132870

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.